Justine Geslin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Justine Geslin has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Chaker El Kalamouni
Unité Mixte Processus Infectieux En Milieu Insulaire Tropical, Université De La Réunion, INSERM U1187, CNRS UMR 9192, IRD UMR 249, Plateforme Technologique CYROI, 94791 Sainte Clotilde, France
1 shared publication - Fanny Roussi
Université Paris-Saclay, CNRS, Institut de Chimie des Substances Naturelles, UPR 2301, 1, Avenue de la Terrasse, 91190 Gif-sur-Yvette, France
1 shared publication - Gwenaëlle Jézéquel
Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) – Helmholtz Centre for Infection Research (HZI), Campus E 8.1, Saarbrücken, Germany, 66123
1 shared publication - Joël Polidori
Institut de Pharmacologie Moléculaire et Cellulaire
1 shared publication - Joëlle Bigay
UMR 7275, Institut de Pharmacologie Moléculaire et Cellulaire, Université Côte d’Azur, CNRS and Inserm, Sophia Antipolis, Valbonne, France
1 shared publication - Jules Fargier
Institut de Chimie des Substances Naturelles
1 shared publication
Latest Publications
- Open Access
- 29 December 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Analogues of Natural Macarangin B Display Potent Antiviral Activity and Better Metabolic Stability
The development of innovative antiviral strategies is critical to address the global health threats posed by RNA viruses, including the Zika virus (ZIKV), which can cause severe neurological complications. The lipid transporter OxySterol Binding Protein (OSBP), essential for cholesterol and phosphatidylinositol 4-phosphate trafficking, is exploited by many positive-strand RNA viruses, making it an attractive novel antiviral target. This study investigates simplified analogues of macarangin B, a natural compound with potent OSBP-targeted antiviral activity against ZIKV, but limited stability due to its flavonol moiety. A series of analogues was synthesized, replacing the flavonol with a flavone core while retaining the essential hexahydroxanthene (HHX) motif. These compounds demonstrated improved stability, high OSBP binding affinity, and low cytotoxicity. The most active compounds exhibited antiviral activity comparable to established OSBP inhibitors and were stable in physiologic media, highlighting their potential as leads for therapeutic development. This work advances the structure-activity relationship (SAR) understanding of macarangin B analogues and provides a foundation for designing effective antivirals targeting in ZIKV infections.
- 29 December 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessAnalogues of Natural Macarangin B Display Potent Antiviral Activity and Better Metabolic Stability
The development of innovative antiviral strategies is critical to address the global health threats posed by RNA viruses, including the Zika virus (ZIKV), which can cause severe neurological complications. The lipid transporter OxySterol Binding Protein (OSBP), essential for cholesterol and phosphatidylinositol 4-phosphate trafficking, is exploited by many positive-strand RNA viruses, making it an attractive novel antiviral target. This study investigates simplified analogues of macarangin B, a natural compound with potent OSBP-targeted antiviral activity against ZIKV, but limited stability due to its flavonol moiety. A series of analogues was synthesized, replacing the flavonol with a flavone core while retaining the essential hexahydroxanthene (HHX) motif. These compounds demonstrated improved stability, high OSBP binding affinity, and low cytotoxicity. The most active compounds exhibited antiviral activity comparable to established OSBP inhibitors and were stable in physiologic media, highlighting their potential as leads for therapeutic development. This work advances the structure-activity relationship (SAR) understanding of macarangin B analogues and provides a foundation for designing effective antivirals targeting in ZIKV infections.